Acthar Gel offers flexible dosing for your patients1
Dosage and frequency should be individualized according to the medical condition, severity of the disease, and initial response of the patient1
- Acthar Gel is administered as a self-injection or given by a caregiver, which gives patients the flexibility to take it at home or wherever is best for them1
- Acthar Gel is a gel preparation designed to provide a prolonged release of medication after injection1
| Recommended Dosing From the Label | Additional Dosing From Clinical Experience With Acthar Gel | |
| Indication | Acthar Gel | DM/PM2 |
| Source | Acthar Gel Prescribing Information | Prospective, open-label proof-of-concept study (N=10)† |
| Injection | Subcutaneous or intramuscular | Subcutaneous |
| Dose* | 40-80 units (0.5-1 mL) |
80 units (1 mL) |
| Schedule | Every 1-3 days | Twice weekly for 24 weeks |
| Indication | Acthar Gel | SLE3 |
| Source | Acthar Gel Prescribing Information | Prospective, open-label study (N=10) |
| Injection | Subcutaneous or intramuscular | Subcutaneous |
| Dose* | 40-80 units (0.5-1 mL) |
80 units (1 mL) |
| Schedule | Every 1-3 days | Once daily for 10 days (optional 5-day extension) |
| Indication | Acthar Gel | Symptomatic Sarcoidosis4 |
| Source | Acthar Gel Prescribing Information | Retrospective chart review (N=47) |
| Injection | Subcutaneous or intramuscular | Subcutaneous or intramuscular |
| Dose* | 40-80 units (0.5-1 mL) |
40-80 units (0.5-1 mL) |
| Schedule | Every 1-3 days | Twice weekly for ≥6 months |
| Indication | Acthar Gel | RA5 |
| Source | Acthar Gel Prescribing Information | Phase 4, two-part, multicenter, randomized withdrawal study (N=259) |
| Injection | Subcutaneous or intramuscular | Subcutaneous |
| Dose* | 40-80 units (0.5-1 mL) |
80 units (1 mL) |
| Schedule | Every 1-3 days | Twice weekly for 12-24 weeks |
| Indication | Acthar Gel | Psoriatic Arthritis6 |
| Source | Acthar Gel Prescribing Information | Prospective, open-label study (N=15) |
| Injection | Subcutaneous or intramuscular | Subcutaneous |
| Dose* | 40-80 units (0.5-1 mL) |
80 units (1 mL) |
| Schedule | Every 1-3 days | Twice weekly for 12-24 weeks |
| Recommended Dosing From the Label |
Additional Dosing From Clinical Experience With Acthar Gel | |||||
| Indication | Acthar Gel | DM/PM2 | SLE3 | Symptomatic Sarcoidosis4 | RA5 | Psoriatic Arthritis6 |
| Source | Acthar Gel Prescribing Information | Prospective, open-label proof-of-concept study (N=10)† |
Prospective, open-label study (N=10) |
Retrospective chart review (N=47) |
Phase 4, two-part, multicenter, randomized withdrawal study (N=259) |
Prospective, open-label study (N=15) |
| Injection | Subcutaneous or intramuscular | Subcutaneous | Subcutaneous | Subcutaneous or intramuscular | Subcutaneous | Subcutaneous |
| Dose* | 40-80 units (0.5-1 mL) | 80 units (1 mL) |
80 units (1 mL) |
40-80 units (0.5-1 mL) |
80 units (1 mL) |
80 units (1 mL) |
| Schedule | Every 1-3 days | Twice weekly for 24 weeks | Once daily for 10 days (optional 5-day extension) | Twice weekly for ≥6 months | Twice weekly for 12-24 weeks | Twice weekly for 12-24 weeks |
*Acthar Gel is provided as a 5-mL multidose vial containing 80 USP units per mL.1
†Ten of the 11 enrolled patients completed the study. One patient dropped out due to heart block unrelated to the study drug and was not included in the efficacy analysis, as she did not complete the minimum 8 weeks of the study drug required for outcome assessment per study protocol.
